Johnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics

Johnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group
                    To Acquire Ortho-Clinical Diagnostics

PR Newswire

NEW BRUNSWICK, N.J., March 31, 2014

NEW BRUNSWICK, N.J., March 31, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE:
JNJ) today announced that it has accepted the binding offer from The Carlyle
Group, which was received and announced on January 16, 2014, to acquire its
Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to
customary adjustments. This acceptance was made after consultation with the
relevant works councils and trade unions. The transaction is expected to close
toward the middle of the year, upon satisfaction of customary closing
conditions.

Johnson & Johnson will discuss any updates during its scheduled quarterly
earnings call on April 15, 2014.

About Ortho-Clinical Diagnostics, Inc.

Ortho-Clinical Diagnostics, Inc. delivers high-quality in vitro diagnostic
products that give healthcare professionals around the world the knowledge
they need to make better treatment decisions sooner. The company serves the
global transfusion medicine community with donor screening and blood typing
products to help ensure every patient receives blood that is safe, the right
type and the right unit. Ortho-Clinical Diagnostics also brings sophisticated
information management, testing technologies and automation and interpretation
tools to clinical laboratories worldwide to help them run more efficiently and
improve patient care. For more information, visit www.orthoclinical.com

About Johnson & Johnson

Caring for the world, one person at a time… inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 128,000 employees at more than 275 Johnson & Johnson
operating companies work with partners in healthcare to touch the lives of
over a billion people every day, throughout the world.

Safe Harbor Statement

This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Ortho-Clinical
Diagnostics, Inc. and/or Johnson & Johnson. Risks and uncertainties include,
but are not limited to: the possibility that the transaction will not be
completed, or if completed, not completed in the expected timeframe; economic
factors, such as interest rate and currency exchange rate fluctuations;
competition, including technological advances, new products and patents
attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; challenges to patents; changes in
behavior and spending patterns or financial distress of purchasers of health
care products and services; changes to governmental laws and regulations and
domestic and foreign health care reforms; general industry conditions
including trends toward health care cost containment; and increased scrutiny
of the health care industry by government agencies. A further list and
description of these risks, uncertainties and other factors can be found in
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended
December 29, 2013, including in Exhibit 99 thereto, and our subsequent filings
with the Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Neither Ortho-Clinical Diagnostics, Inc. nor Johnson & Johnson
undertakes to update any forward-looking statement as a result of new
information or future events or developments.

SOURCE Johnson & Johnson

Website: http://www.jnj.com
Contact: Press: Ernie Knewitz, (732) 524-6623, (917) 697-2318 (M); Investors:
Louise Mehrotra, (732) 524-6491, Sue Hohenleitner, (732) 524-3709
 
Press spacebar to pause and continue. Press esc to stop.